Literature DB >> 19057841

Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.

Masahiro Abe1, Kenji Hiura, Shuji Ozaki, Shinsuke Kido, Toshio Matsumoto.   

Abstract

Multiple myeloma (MM) cell adhesion to stromal cells via very late antigen (VLA)-4 and vascular cell adhesion molecule (VCAM)-1 interaction causes enhanced secretion of osteoclastogenic activity by MM cells. We have reported that MM cell-derived macrophage inflammatory protein (MIP)-1alpha and MIP-1beta are responsible for most of the osteoclastogenic activity in MM. Thus, adhesion-mediated osteoclastogenesis may be caused by enhanced production of MIP-1 via VLA-4-VCAM-1 interaction. The present study was undertaken to clarify whether MM cell-derived MIP-1 plays a role in VLA-4-VCAM-1 adhesion-mediated osteoclastogenesis. Adhesion of MM cells to VCAM-1 upregulated MIP-1alpha and MIP-1beta production from MM cells and enhanced production of osteoclastogenic activity by MM cells. Blockade of MIP-1alpha and MIP-1beta actions not only abrogated elaboration of osteoclastogenic activity, but also suppressed spontaneous MM cell adhesion to VCAM-1. These results demonstrate that MM cell adhesion to VCAM-1 upregulates MIP-1 production by MM cells to cause enhancement of osteoclastogenesis. In addition, the results suggest that the increased production of MIP-1 further enhances MM cell binding to stromal cells via stimulation of VLA-4-VCAM-1 adhesion, forming a "vicious cycle" between MM cell adhesion to stromal cells and MIP-1 production via VLA-4-VCAM-1 interaction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19057841     DOI: 10.1007/s00774-008-0012-z

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  35 in total

1.  Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.

Authors:  Y Nefedova; T H Landowski; W S Dalton
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

2.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Constitutive chemokine production results in activation of leukocyte function-associated antigen-1 on adult T-cell leukemia cells.

Authors:  Y Tanaka; S Mine; C G Figdor; A Wake; H Hirano; J Tsukada; M Aso; K Fujii; K Saito; Y van Kooyk; S Eto
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

Review 4.  Novel therapies targeting the myeloma cell and its bone marrow microenvironment.

Authors:  T Hideshima; D Chauhan; K Podar; R L Schlossman; P Richardson; K C Anderson
Journal:  Semin Oncol       Date:  2001-12       Impact factor: 4.929

5.  A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells.

Authors:  Y Takada; M Kusuda; K Hiura; T Sato; H Mochizuki; Y Nagao; M Tomura; M Yahiro; Y Hakeda; H Kawashima
Journal:  Bone Miner       Date:  1992-06

6.  Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma.

Authors:  L Faid; I Van Riet; M De Waele; T Facon; R Schots; P Lacor; B Van Camp
Journal:  Eur J Haematol       Date:  1996-11       Impact factor: 2.997

7.  A novel membrane antigen selectively expressed on terminally differentiated human B cells.

Authors:  T Goto; S J Kennel; M Abe; M Takishita; M Kosaka; A Solomon; S Saito
Journal:  Blood       Date:  1994-09-15       Impact factor: 22.113

8.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.

Authors:  N Nakagawa; M Kinosaki; K Yamaguchi; N Shima; H Yasuda; K Yano; T Morinaga; K Higashio
Journal:  Biochem Biophys Res Commun       Date:  1998-12-18       Impact factor: 3.575

9.  Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.

Authors:  Toshihiro Hashimoto; Masahiro Abe; Takashi Oshima; Hironobu Shibata; Shuji Ozaki; Daisuke Inoue; Toshio Matsumoto
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

10.  Cancer and the microenvironment: myeloma-osteoclast interactions as a model.

Authors:  Shmuel Yaccoby; Michele J Wezeman; Aminah Henderson; Michele Cottler-Fox; Qing Yi; Bart Barlogie; Joshua Epstein
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

View more
  20 in total

Review 1.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

2.  Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.

Authors:  Michael F Emmons; Anthony W Gebhard; Rajesh R Nair; Rachid Baz; Mark L McLaughlin; Anne E Cress; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2011-10-06       Impact factor: 6.261

Review 3.  Role of RANKL in cancer development and metastasis.

Authors:  Kazuo Okamoto
Journal:  J Bone Miner Metab       Date:  2021-01-02       Impact factor: 2.626

4.  Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection.

Authors:  Weiqiang Chen; Suan-Sin Foo; Adam Taylor; Aleksei Lulla; Andres Merits; Linda Hueston; Mark R Forwood; Nicole C Walsh; Natalie A Sims; Lara J Herrero; Suresh Mahalingam
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

5.  Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

Authors:  Yu-Tzu Tai; Betty Y Chang; Sun-Young Kong; Mariateresa Fulciniti; Guang Yang; Yolanda Calle; Yiguo Hu; Jianhong Lin; Jian-Jun Zhao; Antonia Cagnetta; Michele Cea; Michael A Sellitto; Mike Y Zhong; Qiuju Wang; Chirag Acharya; Daniel R Carrasco; Joseph J Buggy; Laurence Elias; Steven P Treon; William Matsui; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-06-11       Impact factor: 22.113

6.  Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.

Authors:  Qu Cui; Hironobu Shibata; Asuka Oda; Hiroe Amou; Ayako Nakano; Kenichiro Yata; Masahiro Hiasa; Keiichiro Watanabe; Shingen Nakamura; Hirokazu Miki; Takeshi Harada; Shiro Fujii; Kumiko Kagawa; Kyoko Takeuchi; Shuji Ozaki; Toshio Matsumoto; Masahiro Abe
Journal:  Int J Hematol       Date:  2011-06-23       Impact factor: 2.490

Review 7.  Mechanism of action of immunomodulatory agents in multiple myeloma.

Authors:  Thomas Reske; Mariateresa Fulciniti; Nikhil C Munshi
Journal:  Med Oncol       Date:  2010-04-20       Impact factor: 3.064

8.  Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.

Authors:  Kyoko Takeuchi; Masahiro Abe; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Shinsuke Kido; Takeshi Harada; Osamu Tanaka; Hirokazu Miki; Shingen Nakamura; Ayako Nakano; Kumiko Kagawa; Kenichiro Yata; Shuji Ozaki; Toshio Matsumoto
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

9.  Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.

Authors:  Ailing Lu; Manuel A Pallero; Weiqi Lei; Huixian Hong; Yang Yang; Mark J Suto; Joanne E Murphy-Ullrich
Journal:  Am J Pathol       Date:  2016-01-20       Impact factor: 4.307

Review 10.  Bone metastasis: the importance of the neighbourhood.

Authors:  Peter I Croucher; Michelle M McDonald; T John Martin
Journal:  Nat Rev Cancer       Date:  2016-05-25       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.